Loading resource…

European Renal Association (ERA) Immunonephrology Working Group
Lupus nephritis treatment currently relies on glucocorticoids and antiproliferative agents, which often fall short due to toxicity and incomplete efficacy. The document outlines how recent insights into the disease's pathophysiology can inform new treatment paradigms that focus on disease modification. It reviews various emerging therapies targeting specific immune pathways to improve patient outcomes and prevent disease progression.
Sign in to open
Answers use this document only.
Your first question is free.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

CARDIOVASCULAR COMPLICATIONS IN CHRONIC KIDNEY DISEASE: A REVIEW FROM THE EUROPEAN RENAL AND CARDIOVASCULAR MEDICINE WORKING GROUP OF THE EUROPEAN RENAL ASSOCIATION
Same clinical topic · Nephrology

THE ASSOCIATION BETWEEN DUAL RAAS INHIBITION AND RISK OF ACUTE KIDNEY INJURY AND HYPERKALEMIA IN PATIENTS WITH DIABETIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Same clinical topic · Nephrology

OBESITY IN CKD: CORE CURRICULUM 2026
Same clinical topic · Nephrology

OBESITY IN CKD: CORE CURRICULUM 2026
Same clinical topic · Nephrology

ACUTE GLOMERULONEPHRITIS
Same clinical topic · Nephrology

Effects of correction rate for severe hyponatremia in the intensive care unit on patient outcomes
Same clinical topic · Nephrology

CURRENT UNDERSTANDING OF SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS IN CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME
Same clinical topic · Nephrology

A COMPREHENSIVE REVIEW OF ACUTE CARDIO-RENAL SYNDROME: NEED FOR NOVEL BIOMARKERS
Same clinical topic · Nephrology

TIRZEPATIDE AND PREVENTION OF CHRONIC KIDNEY DISEASE
Same clinical topic · Nephrology